🇺🇸 FDA
Pipeline program

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

DCR-PHXC-204

Phase 2 other active

Quick answer

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis for Primary Hyperoxaluria is a Phase 2 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Primary Hyperoxaluria
Phase
Phase 2
Modality
other
Status
active

Clinical trials